Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arazasetron - Sensorion

Next Previous
Drug Profile

Arazasetron - Sensorion

Alternative Names: R-azasetron besylate; R-azasetron besylate - Sensorion; SENS 401

Latest Information Update: 17 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sensorion
  • Class Heterocyclic bicyclo compounds; Oxazines; Small molecules
  • Mechanism of Action Calcineurin inhibitors; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sensorineural hearing loss; Hearing loss
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Sensorineural hearing loss
  • Phase II Hearing loss

Most Recent Events

  • 10 Mar 2025 Sensorion completes enrolment in a phase IIa NOTOXIS trial for Hearing loss (Prevention) in France (NCT05628233)
  • 20 Feb 2025 Sensorion plans a phase II proof of concept study of Arazasetron in Cisplatin induced ototoxicity
  • 23 Sep 2024 Updated efficacy and adverse event data from a phase IIa trial in Hearing loss released by Sensorion

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top